New data presented today for the first time at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated a significant mean placebo-subtracted reduction in A1C(1) of 2.1% from a mean baseline A1C of 8.8% (primary analysis of all patients treated, p less than 0.001) with JANUVIA(TM) (sitagliptin phosphate) 50 mg twice daily and metformin 1000 mg twice daily, a commonly used diabetes therapy, in patients off therapy at randomization. This study included another arm with JANUVIA and a lower dose of metformin and also monotherapy and placebo arms, and full results will be presented later this year. JANUVIA is Merck & Co., Inc.'s investigational oral medicine for type 2 diabetes
